Dr. Reddy’s Laboratories(DRL) has launched aspirin and extended-release Dipyridamole capsules, a therapeutic equivalent generic version of Aggrenox capsules in the U.S.

A trademark of Boehringer Ingelheim, Aggrenox is a combination, anti-platelet drug and it is indicated to reduce risk of stroke in patients. The Aggrenox brand and generic had U.S. sales of approximately $182 million MAT for the 12 months ended October, DRL said, citing IMS Health. DRL said the aspirin and extended-release dipyridamole capsules were available in 25 mg/200 mg strengths.